November 20, 2025

New Publication: Hi-STEMProteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDACNew Publication: Hi-STEM

New Publication: Hi-STEMProteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDACNew Publication: Hi-STEM

Abstract

Objectives: 

To investigate the proteomic profile of different molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and understand their impact on patient outcomes, particularly focusing on pathways involved in xenobiotic metabolism and drug resistance.

Methods: 

The study utilized the serum-free PACO cell culture model and a quantitative prefractionation-based MALDI/MS approach to establish the proteomic profiles of various PDAC subtypes. Differential protein regulation was analyzed to identify systematic alterations in metabolic and drug resistance pathways. Mechanistic studies involved the knockdown and overexpression of key proteins to assess their role in drug resistance.

Results: 

Proteomic analysis revealed subtype-specific alterations, particularly in pathways associated with xenobiotic metabolism and drug resistance. Notably, CYP2S1, a member of the CYP450 family, was upregulated in the HNF1A+ PDAC subtype. CYP2S1 levels were further inducible by polyaromatic hydrocarbons (PAHs) and SN38, the active metabolite of irinotecan via AHR. Mechanistic studies demonstrated that knockdown of AHR or CYP2S1 sensitized PDAC cells to SN38, whereas overexpression of CYP2S1 increased resistance to SN38.

Conclusions: 

The findings highlight the significant role of CYP2S1 in mediating drug resistance in certain PDAC subtypes. Targeting CYP2S1 and its regulatory pathways could enhance the efficacy of chemotherapeutic agents like irinotecan in treating PDAC. These results provide new insights into the molecular mechanisms underlying PDAC subtype-specific drug resistance and suggest potential therapeutic targets.


Thiel, Vera PhD,†; Nadler, Wiebke M. PhD,†; Kerner, Alexander PhD,†; Kuhlmann, Laura PhD,†,‡; Reitberger, Manuel PhD,†; Vorberg, Tim,†; Schwerd-Kleine, Paul,†; Noll, Elisa PhD; Giese, Nathalia A. MD; Yen, Hsi-Yu Dr. med. vet.§,∥,¶; Steiger, Katja Dr. med. vet.§; Vogel, Vanessa,†,#; Klein, Corinna,†; Hackert, Thilo MD*; Koschny, Ronald MD††; Opitz, Christiane A. PhD; Trumpp, Andreas PhD,†; Sprick, Martin R. PhD,†; Rösli, Christoph PhD*,†. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Pancreas ():10.1097/MPA.0000000000002553, August 29, 2025. | DOI: 10.1097/MPA.0000000000002553

Our latest News

discover more
One device – two organs: Simultaneous perfusion opens up new possibilities for future multi-organ transplants

One device – two organs: Simultaneous perfusion opens up new possibilities for future multi-organ transplants

A key factor in the success of an organ transplant is the condition of the donated organ at the time of implantation. Preserving the organ prior to transplantation using machine perfusion plays a crucial role in this process. This procedure has now been implemented particularly efficiently at Heidelberg University Hospital (UKHD): as part of a […]

Award-winning: Concept for “the perfect stroke room”

Award-winning: Concept for “the perfect stroke room”

UKHD wins DGN Nursing Award 2025 for its “Stroke Unit Innovation Room” project. Full Text in German below. Ausgezeichnet: Konzept für „das perfekte Schlaganfallzimmer“ UKHD gewinnt DGN-Pflegepreis 2025 für das Projekt „Innovationszimmer Stroke Unit“ Das Universitätsklinikum Heidelberg (UKHD) ist mit dem Pflegepreis der Deutschen Gesellschaft für Neurologie (DGN) ausgezeichnet worden. Prämiert wurde das Projekt „Innovationszimmer […]

FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer

FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer

Promega’s MSI technology will help identify patients with microsatellite stable (MSS) endometrial cancer Full Text in German below. Die FDA genehmigt das Promega OncoMate® MSI Dx Analysis System als Begleitdiagnostikum für KEYTRUDA® in Kombination mit LENVIMA® bei fortgeschrittenem Endometriumkarzinom  Die MSI-Technologie von Promega wird bei der Identifizierung von Patientinnen mit mikrosatellitenstabilem (MSS) Endometriumkarzinom helfen Madison, […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp